Eli Lilly and (LLY) Given “Buy” Rating at Jefferies Group

Eli Lilly and (NYSE:LLY)‘s stock had its “buy” rating reissued by investment analysts at Jefferies Group in a research report issued on Friday. They currently have a $91.00 price objective on the stock. Jefferies Group’s price target would suggest a potential upside of 21.72% from the stock’s current price. Jefferies Group also issued estimates for Eli Lilly and’s FY2019 earnings at $5.25 EPS.

LLY has been the subject of a number of other research reports. BMO Capital Markets increased their price objective on Eli Lilly and from $73.00 to $74.00 and gave the company an “underperform” rating in a research note on Thursday, February 1st. Credit Suisse Group reissued a “hold” rating on shares of Eli Lilly and in a research note on Wednesday, December 13th. JPMorgan Chase & Co. set a $105.00 price objective on Eli Lilly and and gave the company a “buy” rating in a research note on Monday, February 26th. TheStreet lowered Eli Lilly and from a “b” rating to a “c” rating in a research note on Monday, March 5th. Finally, Bank of America dropped their price objective on Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating for the company in a research note on Thursday, February 1st. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company. Eli Lilly and has a consensus rating of “Hold” and a consensus target price of $93.37.

Eli Lilly and (LLY) opened at $74.76 on Friday. Eli Lilly and has a 52-week low of $73.69 and a 52-week high of $89.09. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.01 and a current ratio of 1.32. The company has a market cap of $83,846.11, a P/E ratio of -373.78, a price-to-earnings-growth ratio of 1.39 and a beta of 0.28.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. The firm had revenue of $6.16 billion during the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.95 earnings per share. equities research analysts predict that Eli Lilly and will post 4.87 EPS for the current fiscal year.

In related news, insider Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $81.09, for a total value of $72,981.00. Following the completion of the sale, the insider now owns 4,130 shares of the company’s stock, valued at $334,901.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jeffrey N. Simmons sold 9,625 shares of the firm’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $81.12, for a total value of $780,780.00. Following the completion of the sale, the senior vice president now directly owns 152,120 shares of the company’s stock, valued at approximately $12,339,974.40. The disclosure for this sale can be found here. Insiders sold 15,261 shares of company stock valued at $1,225,085 in the last ninety days. 0.20% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Candriam Luxembourg S.C.A. raised its holdings in Eli Lilly and by 166.7% in the third quarter. Candriam Luxembourg S.C.A. now owns 430,424 shares of the company’s stock worth $36,818,000 after purchasing an additional 269,038 shares in the last quarter. Chevy Chase Trust Holdings Inc. raised its holdings in Eli Lilly and by 1.0% in the third quarter. Chevy Chase Trust Holdings Inc. now owns 851,985 shares of the company’s stock worth $72,879,000 after purchasing an additional 8,328 shares in the last quarter. Exane Derivatives raised its holdings in Eli Lilly and by 2,838.2% in the fourth quarter. Exane Derivatives now owns 18,687 shares of the company’s stock worth $1,578,000 after purchasing an additional 18,051 shares in the last quarter. BARING ASSET MANAGEMENT Ltd raised its holdings in Eli Lilly and by 114.6% in the third quarter. BARING ASSET MANAGEMENT Ltd now owns 43,492 shares of the company’s stock worth $3,721,000 after purchasing an additional 23,229 shares in the last quarter. Finally, Bank of the Ozarks raised its holdings in Eli Lilly and by 18.0% in the third quarter. Bank of the Ozarks now owns 10,068 shares of the company’s stock worth $861,000 after purchasing an additional 1,535 shares in the last quarter. Institutional investors and hedge funds own 77.62% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3291027/eli-lilly-and-lly-rating-reiterated-by-jefferies-group.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Heidrick & Struggles  Expected to Post Q2 2018 Earnings of $0.43 Per Share
Heidrick & Struggles Expected to Post Q2 2018 Earnings of $0.43 Per Share
TheStreet Lowers Acxiom  to C+
TheStreet Lowers Acxiom to C+
TheStreet Downgrades Gridsum  to D
TheStreet Downgrades Gridsum to D
Stifel Nicolaus Cuts Williams Pipeline Partners  Price Target to $41.00
Stifel Nicolaus Cuts Williams Pipeline Partners Price Target to $41.00
Cowen Initiates Coverage on Unum Therapeutics
Cowen Initiates Coverage on Unum Therapeutics
OneSmart International Education Group  Earns Overweight Rating from Analysts at Morgan Stanley
OneSmart International Education Group Earns Overweight Rating from Analysts at Morgan Stanley


© 2006-2018 Ticker Report. Google+.